Millennium group reports 3.85M shares (5.5%) in Quoin

Quoin Pharmaceuticals Ltd. Schedule 13G: a group led by Millennium affiliates and Israel A. Englander reports shared beneficial ownership of 3,850,385 ordinary shares, representing 5.5% of the class, per cover-page disclosures.

Rhea-AI Filing Summary

Quoin Pharmaceuticals Ltd. Schedule 13G: a group led by Millennium affiliates and Israel A. Englander reports shared beneficial ownership of 3,850,385 ordinary shares, representing 5.5% of the class, per cover-page disclosures. The filers executed a Joint Filing Agreement dated June 1, 2026. The filing notes CUSIP 74907L409 and that each American Depositary Share represents thirty-five Ordinary Shares.

Insights

Securities Law Analyst

Schedules 13G show passive/collective holdings and group coordination.

The filing lists Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander as joint filers and discloses shared voting and dispositive power over 3,850,385 shares (listed as 5.5%). The filing includes a Joint Filing Agreement dated June 1, 2026.

Legal consequences hinge on classification rules for beneficial ownership and group filing obligations; subsequent Schedule 13D/13G amendments would update any change in intent or ownership levels.

Equity Investor Relations Specialist

Holders report a minority, non‑controlling stake disclosed for transparency.

The reported 5.5% stake is a public disclosure of a minority position; the filing states that shares are held by entities under voting control or investment discretion of Millennium affiliates and Mr. Englander. The filing expressly refrains from admitting beneficial ownership beyond the stated figures.

Future amendments would be expected if the group’s intent or percentage ownership changes; timing and cash‑flow treatment are not provided in the excerpt.

Key Figures

Reported shares beneficially owned: 3,850,385 shares Percent of class: 5.5% CUSIP: 74907L409 +2 more

5 metrics

Reported shares beneficially owned 3,850,385 shares Amount reported with shared voting/dispositive power

Percent of class 5.5% Percent of ordinary shares reported on cover pages

CUSIP 74907L409 Identifier shown for American Depositary Shares

ADS conversion ratio 1 ADS = 35 Ordinary Shares Statement that each American Depositary Share represents thirty-five Ordinary Shares

Joint Filing Agreement date June 1, 2026 Date of Joint Filing Agreement among filers

Key Terms

Schedule 13G, shared dispositive power, American Depositary Share

3 terms

Schedule 13G regulatory

"Item 1. Name of issuer: Quoin Pharmaceuticals Ltd.; form type Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

shared dispositive power regulatory

"Shared Dispositive Power 3,850,385.00 listed on cover pages"

American Depositary Share financial

"Each American Depositary Share represents thirty-five Ordinary Shares"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Millennium report in Quoin Pharmaceuticals (QNRX)?

The filing reports a shared beneficial interest of 3,850,385 ordinary shares, equal to 5.5% of the class. The ownership is reported by Millennium affiliates and Israel A. Englander under a joint filing agreement dated June 1, 2026.

Does the Schedule 13G indicate control of Quoin Pharmaceuticals (QNRX)?

No controlling interest is asserted; the filing discloses shared voting and dispositive power over 3,850,385 shares (5.5%). The document does not claim board control or a change in corporate governance.

What securities and CUSIP are referenced in the filing for QNRX?

The filing references Ordinary Shares, no par value and CUSIP 74907L409. It also states each American Depositary Share represents thirty-five Ordinary Shares.

Who signed the joint filing and when was it executed?

A Joint Filing Agreement among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander is dated June 1, 2026. Signatures in the excerpt include Gil Raviv and Israel A. Englander dated 06/01/2026.

Are the shares reported as solely held by Israel A. Englander?

No. The filing states the shares are held by entities subject to voting control and investment discretion by Millennium affiliates and/or other managers; it does not attribute sole beneficial ownership to Mr. Englander.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 05:14 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Quoin Pharmaceuticals Ltd.

(Name of Issuer)

Ordinary Shares, no par value per share

(Title of Class of Securities)

74907L409

(CUSIP Number)

05/26/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 74907L409

1

Names of Reporting Persons

Integrated Core Strategies (US) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,850,385.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,850,385.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,850,385.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 74907L409

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,850,385.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,850,385.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,850,385.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 74907L409

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,850,385.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,850,385.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,850,385.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 74907L409

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,850,385.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,850,385.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,850,385.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quoin Pharmaceuticals Ltd.
(b)	Address of issuer's principal executive offices: 42127 Pleasant Forest Court, Ashburn, Virginia 20148-7349
Item 2.
(a)	Name of person filing: Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Ordinary Shares, no par value per share
(e)	CUSIP Number(s): 74907L409
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Integrated Core Strategies (US) LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/01/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/01/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	06/01/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	06/01/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner CUSIP number 74907L409 has been assigned to the issuer's American Depositary Shares. Each American Depositary Share represents thirty-five Ordinary Shares. No CUSIP number has been assigned to the issuer's Ordinary Shares.

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of June 1, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.